Drug Profile
Research programme: secondary hyperparathyroidism therapies - OPKO Renal
Alternative Names: CTA 091Latest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator OPKO Renal
- Class Vitamin D analogues
- Mechanism of Action CYP24 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Secondary hyperparathyroidism
Most Recent Events
- 29 Mar 2023 Discontinued - Preclinical for Secondary hyperparathyroidism in USA (unspecified route)
- 28 May 2018 No recent reports of development identified for preclinical development in Secondary-hyperparathyroidism in USA
- 24 Apr 2014 Preclinical trials in Secondary hyperparathyroidism in USA (unspecified route)